Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Retinal Vein Occlusion Therapeutics market. The report identifies the key trends shaping and driving the global Retinal Vein Occlusion Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Retinal Vein Occlusion Therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Retinal Vein Occlusion Therapeutics market. Its scope includes -
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
Summary
GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Retinal Vein Occlusion Therapeutics market. The report identifies the key trends shaping and driving the global Retinal Vein Occlusion Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Retinal Vein Occlusion Therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Retinal Vein Occlusion Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Retinal Vein Occlusion Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Retinal Vein Occlusion Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Retinal Vein Occlusion Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Retinal Vein Occlusion Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Retinal Vein Occlusion Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Retinal Vein Occlusion Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Retinal Vein Occlusion Therapeutics market landscape? – Identify, understand and capitalize.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 RETINAL VEIN OCCLUSION THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.1.1 Types of Retinal Vein Occlusion
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Incidence
2.2.3 Mortality/Morbidity
2.2.4 Sex
2.2.5 Age
2.2.6 Quality of Life
2.2.7 Pharmacoeconomic Burden
2.3 Etiology and Risk Factors
2.3.1 Systemic Vascular/Atherosclerotic Risk Factors in Retinal Vein Occlusion
2.3.2 Hematological Disorders and other Systemic Conditions
2.3.3 Glaucoma/Ocular Hypertension
2.3.4 Familial Retinal Vein Occlusion
2.4 Pathophysiology
2.5 Signs and Symptoms
2.5.1 Macular Edema
2.5.2 Neovascularization
2.5.3 Neovascular Glaucoma
2.6 Diagnosis
2.7 Treatment and Management Pattern
2.7.1 Medical Approaches for Retinal Vein Occlusion
2.7.2 Laser Treatment
2.7.3 Common Surgical Approaches for Retinal Vein Occlusion
2.7.4 Pharmacological Approaches for Retinal Vein Occlusion
2.7.5 Management of Retinal Vein Occlusion
2.8 Referral Pathway
2.9 GlobalData Pipeline Report Guidance
3 RETINAL VEIN OCCLUSION THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Global
3.2 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Global
3.3 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - The US
3.4 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - The US
3.5 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - France
3.6 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - France
3.7 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Germany
3.8 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Germany
3.9 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Italy
3.10 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Italy
3.11 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Spain
3.12 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Spain
3.13 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - The UK
3.14 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - The UK
3.15 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Japan
3.16 Retinal Vein Occlusion Therapeutics Market Forecast (2010- 2019) - Japan
3.17 Drivers and Barriers for the Retinal Vein Occlusion Therapeutics Market
3.17.1 Drivers for the Retinal Vein Occlusion Therapeutics Market
3.17.2 Barriers for the Retinal Vein Occlusion Therapeutics Market
3.17.3 Opportunity and Unmet Need Analysis
3.18 Key Takeaway
4 RETINAL VEIN OCCLUSION THERAPEUTICS - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Retinal Vein Occlusion Therapeutics Market
4.3.1 Lucentis (ranibizumab)
4.3.2 Ozurdex (dexamethasone intravitreal implant)
4.3.3 Avastin (bevacizumab)
4.4 Key Takeaway
5 RETINAL VEIN OCCLUSION THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Retinal Vein Occlusion Therapeutics Pipeline - Pipeline by Phase of Development
5.3.1 Retinal Vein Occlusion Therapeutics - Phase III Pipeline
5.3.2 Retinal Vein Occlusion Therapeutics - Phase II/III Pipeline
5.3.3 Retinal Vein Occlusion Therapeutics - Phase II Pipeline
5.3.4 Retinal Vein Occlusion Therapeutics - Phase I/II
5.4 Retinal Vein Occlusion Therapeutics Market - Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Retinal Vein Occlusion Therapeutics - Promising Drugs under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 Eylea (aflibercept injection)
5.8 Key Takeaway
6 RETINAL VEIN OCCLUSION THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trial Mapping Overview
6.2 Clinical Trials by Region/Country (the US, EU5 and Japan)
6.3 Clinical Trials by Phase
6.4 Clinical Trials by Trial Status
6.5 Prominent Sponsors
6.6 Key Companies Participating in Retinal Vein Occlusion Therapeutics Clinical Trials
7 STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Retinal Vein Occlusion Therapeutics: Implications for Future Market Competition
8 RETINAL VEIN OCCLUSION THERAPEUTICS - FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Regeneron Pharmaceuticals, Inc
8.2.2 Novartis AG
8.2.3 Roche (Genentech)
8.2.4 Allergan
9 RETINAL VEIN OCCLUSION THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS
10 RETINAL VEIN OCCLUSION THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Forecasting
10.4.4 Primary Research
10.4.5 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer
LIST OF TABLES
Table 1: Prevalence Rates of Retinal Vein Occlusion by Country/Region
Table 2: Prevalent Pool of Retinal Vein Occlusion Patients in the Seven Major Markets
Table 3: Recommendations for the Management of Branch Retinal Vein Occlusion
Table 4: Recommendations for the Management of Central Retinal Vein Occlusion
Table 5: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2006- 2011
Table 6: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2011- 2019
Table 7: Retinal Vein Occlusion Therapeutics Market, The US, Revenue ($m), 2006- 2011
Table 8: Retinal Vein Occlusion Therapeutics Market, The US, Forecasts ($m), 2011- 2019
Table 9: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2006- 2011
Table 10: Retinal Vein Occlusion Therapeutics Market, France, Forecasts ($m), 2011- 2019
Table 11: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2006- 2011
Table 12: Retinal Vein Occlusion Therapeutics Market, Germany, Forecasts ($m), 2011- 2019
Table 13: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2006- 2011
Table 14: Retinal Vein Occlusion Therapeutics Market, Italy, Forecasts ($m), 2011- 2019
Table 15: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2006- 2011
Table 16: Retinal Vein Occlusion Therapeutics Market, Spain, Forecasts ($m), 2011- 2019
Table 17: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2006- 2011
Table 18: Retinal Vein Occlusion Therapeutics Market, The UK, Forecasts ($m), 2011- 2019
Table 19: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2006- 2011
Table 20: Retinal Vein Occlusion Therapeutics Market, Japan, Forecasts ($m), 2011- 2019
Table 21: Lucentis Phase III Clinical Trial Details
Table 22: Number (%) of Patients With ≥ 15 Letter Improvement from Baseline in Best-Corrected Visual Acuity
Table 23: Adverse Reactions Reported by >2% of Patients in the First Six Months
Table 24: Retinal Vein Occlusion Therapeutics, Phase III Pipeline, 2012
Table 25: Retinal Vein Occlusion Therapeutics, Phase II/III Pipeline, 2012
Table 26: Retinal Vein Occlusion Therapeutics, Phase II Pipeline, 2012
Table 27: Retinal Vein Occlusion Therapeutics, Phase I/II Pipeline, 2012
Table 28: RVO Therapeutics - Most Promising Drugs Under Clinical Development, 2012
Table 29: Eylea Phase III Clinical Trial Details
Table 30: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2012
Table 31: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase, 2012
Table 32: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status, 2012
Table 33: Retinal Vein Occlusion Therapeutics, Prominent Sponsors, 2012
Table 34: Retinal Vein Occlusion Therapeutics, Global, Key Companies Participating Clinical Trials, 2012
Table 35: Regeneron - Ophthalmology Pipeline Products, 2012
Table 36: Novartis - Ophthalmology Pipeline Products, 2012
Table 37: Roche - Ophthalmology Pipeline Products, 2012
Table 38: Allergan, Inc. - Ophthalmology Pipeline Products, 2012
Table 39: Retinal Vein Occlusion Therapeutics, Global, Deals, 2009-2011
LIST OF FIGURES
Figure 1: Branch Retinal Vein Occlusion
Figure 2: Central Vein Retinal Occlusion
Figure 3: Ischemic Central Retinal Vein Occlusion
Figure 4: Nonischemic Central Retinal Vein Occlusion
Figure 5: KOL Insights, Future Trends in the Prevalence for the RVO in the US and Europe
Figure 6: Pharmacoeconomic Burden of Retinal Vein Occlusion
Figure 7: Branch Retinal Vein Occlusion in the Superotemporal Quadrant of the Right Eye
Figure 8: Nonperfused Central Retinal Vein Occlusion in the Left Eye
Figure 9: Assessment of Cardiovascular Risk in Patients with Retinal Vein Occlusion
Figure 10: KOL Insights, Treatment and Management Patterns
Figure 11: KOL Insights, Usage Patterns for the Pharmacological Treatment Options
Figure 12: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2006- 2011
Figure 13: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2011- 2019
Figure 14: Retinal Vein Occlusion Therapeutics Market, The US, , Revenue ($m), 2006- 2011
Figure 15: Retinal Vein Occlusion Therapeutics Market, The US, Forecast ($m), 2011- 2019
Figure 16: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2006- 2011
Figure 17: Retinal Vein Occlusion Therapeutics Market, France, Forecast ($m), 2011- 2019
Figure 18: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2006- 2011
Figure 19: Retinal Vein Occlusion Therapeutics Market, Germany, Forecast ($m), 2011- 2019
Figure 20: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2006- 2011
Figure 21: Retinal Vein Occlusion Therapeutics Market, Italy, Forecast ($m), 2011- 2019
Figure 22: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2006- 2011
Figure 23: Retinal Vein Occlusion Therapeutics Market, Spain, Forecast ($m), 2011- 2019
Figure 24: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2006- 2011
Figure 25: Retinal Vein Occlusion Therapeutics Market, The UK, Forecast ($m), 2011- 2019
Figure 26: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2006- 2011
Figure 27: Retinal Vein Occlusion Therapeutics Market, Japan, Forecast ($m), 2011- 2019
Figure 28: Opportunity and Unmet Need in the Retinal Vein Occlusion Therapeutics Market, 2012
Figure 29: Retinal Vein Occlusion Therapeutics, Strategic Competitor Assessment, 2012
Figure 30:KOL Insights, Potential Future Pipeline Assets in Retinal Vein Occlusion Therapeutics
Figure 31: Retinal Vein Occlusion Therapeutics - Pipeline by Phase of Development, 2012
Figure 32: Retinal Vein Occlusion Therapeutics, Pipeline by Mechanism of Action, 2012
Figure 33: Retinal Vein Occlusion Therapeutics, Technology Trends Analytics Framework, 2012
Figure 34: Retinal Vein Occlusion Pipeline, Technology Trends Analytics Framework, Description, 2012
Figure 35: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2012
Figure 36: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase (%), 2012
Figure 37: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status (%), 2012
Figure 38: Retinal Vein Occlusion Therapeutics, Overall Sponsors (%), 2012
Figure 39: Retinal Vein Occlusion Therapeutics, Prominent Sponsors (%), 2012
Figure 40: Retinal Vein Occlusion Therapeutics, Global, Key Companies Participating Clinical Trials, 2012
Figure 41: Retinal Vein Occlusion Therapeutics Market, Drivers and Barriers, 2012
Figure 42: Implications for Future Market Competition in the Retinal Vein Occlusion Therapeutics Market, 2012
Figure 43: GlobalData Market Size Estimation
Figure 44: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Regeneron Pharmaceuticals, Inc
Novartis AG
Roche (Genentech)
Allergan
1.1 List of Tables
1.2 List of Figures
2 RETINAL VEIN OCCLUSION THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.1.1 Types of Retinal Vein Occlusion
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Incidence
2.2.3 Mortality/Morbidity
2.2.4 Sex
2.2.5 Age
2.2.6 Quality of Life
2.2.7 Pharmacoeconomic Burden
2.3 Etiology and Risk Factors
2.3.1 Systemic Vascular/Atherosclerotic Risk Factors in Retinal Vein Occlusion
2.3.2 Hematological Disorders and other Systemic Conditions
2.3.3 Glaucoma/Ocular Hypertension
2.3.4 Familial Retinal Vein Occlusion
2.4 Pathophysiology
2.5 Signs and Symptoms
2.5.1 Macular Edema
2.5.2 Neovascularization
2.5.3 Neovascular Glaucoma
2.6 Diagnosis
2.7 Treatment and Management Pattern
2.7.1 Medical Approaches for Retinal Vein Occlusion
2.7.2 Laser Treatment
2.7.3 Common Surgical Approaches for Retinal Vein Occlusion
2.7.4 Pharmacological Approaches for Retinal Vein Occlusion
2.7.5 Management of Retinal Vein Occlusion
2.8 Referral Pathway
2.9 GlobalData Pipeline Report Guidance
3 RETINAL VEIN OCCLUSION THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Global
3.2 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Global
3.3 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - The US
3.4 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - The US
3.5 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - France
3.6 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - France
3.7 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Germany
3.8 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Germany
3.9 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Italy
3.10 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Italy
3.11 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Spain
3.12 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Spain
3.13 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - The UK
3.14 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - The UK
3.15 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Japan
3.16 Retinal Vein Occlusion Therapeutics Market Forecast (2010- 2019) - Japan
3.17 Drivers and Barriers for the Retinal Vein Occlusion Therapeutics Market
3.17.1 Drivers for the Retinal Vein Occlusion Therapeutics Market
3.17.2 Barriers for the Retinal Vein Occlusion Therapeutics Market
3.17.3 Opportunity and Unmet Need Analysis
3.18 Key Takeaway
4 RETINAL VEIN OCCLUSION THERAPEUTICS - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Retinal Vein Occlusion Therapeutics Market
4.3.1 Lucentis (ranibizumab)
4.3.2 Ozurdex (dexamethasone intravitreal implant)
4.3.3 Avastin (bevacizumab)
4.4 Key Takeaway
5 RETINAL VEIN OCCLUSION THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Retinal Vein Occlusion Therapeutics Pipeline - Pipeline by Phase of Development
5.3.1 Retinal Vein Occlusion Therapeutics - Phase III Pipeline
5.3.2 Retinal Vein Occlusion Therapeutics - Phase II/III Pipeline
5.3.3 Retinal Vein Occlusion Therapeutics - Phase II Pipeline
5.3.4 Retinal Vein Occlusion Therapeutics - Phase I/II
5.4 Retinal Vein Occlusion Therapeutics Market - Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Retinal Vein Occlusion Therapeutics - Promising Drugs under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 Eylea (aflibercept injection)
5.8 Key Takeaway
6 RETINAL VEIN OCCLUSION THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trial Mapping Overview
6.2 Clinical Trials by Region/Country (the US, EU5 and Japan)
6.3 Clinical Trials by Phase
6.4 Clinical Trials by Trial Status
6.5 Prominent Sponsors
6.6 Key Companies Participating in Retinal Vein Occlusion Therapeutics Clinical Trials
7 STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Retinal Vein Occlusion Therapeutics: Implications for Future Market Competition
8 RETINAL VEIN OCCLUSION THERAPEUTICS - FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Regeneron Pharmaceuticals, Inc
8.2.2 Novartis AG
8.2.3 Roche (Genentech)
8.2.4 Allergan
9 RETINAL VEIN OCCLUSION THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS
10 RETINAL VEIN OCCLUSION THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Forecasting
10.4.4 Primary Research
10.4.5 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer
LIST OF TABLES
Table 1: Prevalence Rates of Retinal Vein Occlusion by Country/Region
Table 2: Prevalent Pool of Retinal Vein Occlusion Patients in the Seven Major Markets
Table 3: Recommendations for the Management of Branch Retinal Vein Occlusion
Table 4: Recommendations for the Management of Central Retinal Vein Occlusion
Table 5: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2006- 2011
Table 6: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2011- 2019
Table 7: Retinal Vein Occlusion Therapeutics Market, The US, Revenue ($m), 2006- 2011
Table 8: Retinal Vein Occlusion Therapeutics Market, The US, Forecasts ($m), 2011- 2019
Table 9: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2006- 2011
Table 10: Retinal Vein Occlusion Therapeutics Market, France, Forecasts ($m), 2011- 2019
Table 11: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2006- 2011
Table 12: Retinal Vein Occlusion Therapeutics Market, Germany, Forecasts ($m), 2011- 2019
Table 13: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2006- 2011
Table 14: Retinal Vein Occlusion Therapeutics Market, Italy, Forecasts ($m), 2011- 2019
Table 15: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2006- 2011
Table 16: Retinal Vein Occlusion Therapeutics Market, Spain, Forecasts ($m), 2011- 2019
Table 17: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2006- 2011
Table 18: Retinal Vein Occlusion Therapeutics Market, The UK, Forecasts ($m), 2011- 2019
Table 19: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2006- 2011
Table 20: Retinal Vein Occlusion Therapeutics Market, Japan, Forecasts ($m), 2011- 2019
Table 21: Lucentis Phase III Clinical Trial Details
Table 22: Number (%) of Patients With ≥ 15 Letter Improvement from Baseline in Best-Corrected Visual Acuity
Table 23: Adverse Reactions Reported by >2% of Patients in the First Six Months
Table 24: Retinal Vein Occlusion Therapeutics, Phase III Pipeline, 2012
Table 25: Retinal Vein Occlusion Therapeutics, Phase II/III Pipeline, 2012
Table 26: Retinal Vein Occlusion Therapeutics, Phase II Pipeline, 2012
Table 27: Retinal Vein Occlusion Therapeutics, Phase I/II Pipeline, 2012
Table 28: RVO Therapeutics - Most Promising Drugs Under Clinical Development, 2012
Table 29: Eylea Phase III Clinical Trial Details
Table 30: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2012
Table 31: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase, 2012
Table 32: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status, 2012
Table 33: Retinal Vein Occlusion Therapeutics, Prominent Sponsors, 2012
Table 34: Retinal Vein Occlusion Therapeutics, Global, Key Companies Participating Clinical Trials, 2012
Table 35: Regeneron - Ophthalmology Pipeline Products, 2012
Table 36: Novartis - Ophthalmology Pipeline Products, 2012
Table 37: Roche - Ophthalmology Pipeline Products, 2012
Table 38: Allergan, Inc. - Ophthalmology Pipeline Products, 2012
Table 39: Retinal Vein Occlusion Therapeutics, Global, Deals, 2009-2011
LIST OF FIGURES
Figure 1: Branch Retinal Vein Occlusion
Figure 2: Central Vein Retinal Occlusion
Figure 3: Ischemic Central Retinal Vein Occlusion
Figure 4: Nonischemic Central Retinal Vein Occlusion
Figure 5: KOL Insights, Future Trends in the Prevalence for the RVO in the US and Europe
Figure 6: Pharmacoeconomic Burden of Retinal Vein Occlusion
Figure 7: Branch Retinal Vein Occlusion in the Superotemporal Quadrant of the Right Eye
Figure 8: Nonperfused Central Retinal Vein Occlusion in the Left Eye
Figure 9: Assessment of Cardiovascular Risk in Patients with Retinal Vein Occlusion
Figure 10: KOL Insights, Treatment and Management Patterns
Figure 11: KOL Insights, Usage Patterns for the Pharmacological Treatment Options
Figure 12: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2006- 2011
Figure 13: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2011- 2019
Figure 14: Retinal Vein Occlusion Therapeutics Market, The US, , Revenue ($m), 2006- 2011
Figure 15: Retinal Vein Occlusion Therapeutics Market, The US, Forecast ($m), 2011- 2019
Figure 16: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2006- 2011
Figure 17: Retinal Vein Occlusion Therapeutics Market, France, Forecast ($m), 2011- 2019
Figure 18: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2006- 2011
Figure 19: Retinal Vein Occlusion Therapeutics Market, Germany, Forecast ($m), 2011- 2019
Figure 20: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2006- 2011
Figure 21: Retinal Vein Occlusion Therapeutics Market, Italy, Forecast ($m), 2011- 2019
Figure 22: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2006- 2011
Figure 23: Retinal Vein Occlusion Therapeutics Market, Spain, Forecast ($m), 2011- 2019
Figure 24: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2006- 2011
Figure 25: Retinal Vein Occlusion Therapeutics Market, The UK, Forecast ($m), 2011- 2019
Figure 26: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2006- 2011
Figure 27: Retinal Vein Occlusion Therapeutics Market, Japan, Forecast ($m), 2011- 2019
Figure 28: Opportunity and Unmet Need in the Retinal Vein Occlusion Therapeutics Market, 2012
Figure 29: Retinal Vein Occlusion Therapeutics, Strategic Competitor Assessment, 2012
Figure 30:KOL Insights, Potential Future Pipeline Assets in Retinal Vein Occlusion Therapeutics
Figure 31: Retinal Vein Occlusion Therapeutics - Pipeline by Phase of Development, 2012
Figure 32: Retinal Vein Occlusion Therapeutics, Pipeline by Mechanism of Action, 2012
Figure 33: Retinal Vein Occlusion Therapeutics, Technology Trends Analytics Framework, 2012
Figure 34: Retinal Vein Occlusion Pipeline, Technology Trends Analytics Framework, Description, 2012
Figure 35: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2012
Figure 36: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase (%), 2012
Figure 37: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status (%), 2012
Figure 38: Retinal Vein Occlusion Therapeutics, Overall Sponsors (%), 2012
Figure 39: Retinal Vein Occlusion Therapeutics, Prominent Sponsors (%), 2012
Figure 40: Retinal Vein Occlusion Therapeutics, Global, Key Companies Participating Clinical Trials, 2012
Figure 41: Retinal Vein Occlusion Therapeutics Market, Drivers and Barriers, 2012
Figure 42: Implications for Future Market Competition in the Retinal Vein Occlusion Therapeutics Market, 2012
Figure 43: GlobalData Market Size Estimation
Figure 44: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Regeneron Pharmaceuticals, Inc
Novartis AG
Roche (Genentech)
Allergan
